Something that concerns me about RVX, which could be slowing down talks with BP, is that the company does not seem to have the necessary experience at a senior level in some of the areas in which ABL has clinical potential. The breadth of ABL's potential use is of course is exceptional - ACS, CHF, CKD, T2D, PH, covid, HIV, and more. But where are the insiders with track records as clinical researchers or management in these very different fields? The only real expertise I'm aware of is in lipids and metabolic diseases. How can they talk to BP specialists on anything outside those fields? The company can employ external consultants to do a lot of things, but not negotiate with BP.
If it all rests on Don's shoulders it could explain a lot. Or am I missing something?